shutterstock_1625917948_nitpicker
nitpicker / Shutterstock.com
23 November 2021GenericsMuireann Bolger

Bayer, Onyx drop Nexavar patent suit

Bayer Healthcare and Amgen subsidiary Onyx Pharmaceuticals have dropped a patent infringement suit against Dr Reddy’s over a planned generic version of cancer treatment Nexavar (sorafenib).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
22 December 2015   Germany-based healthcare company Bayer HealthCare has sued Mylan Pharmaceuticals over the alleged infringement of five of its patents.
Asia
16 July 2014   The Mumbai High Court has upheld India-based Natco Pharma’s compulsory licence on Bayer’s kidney cancer drug Nexavar (sorafenib).

More on this story

Big Pharma
22 December 2015   Germany-based healthcare company Bayer HealthCare has sued Mylan Pharmaceuticals over the alleged infringement of five of its patents.
Asia
16 July 2014   The Mumbai High Court has upheld India-based Natco Pharma’s compulsory licence on Bayer’s kidney cancer drug Nexavar (sorafenib).

More on this story

Big Pharma
22 December 2015   Germany-based healthcare company Bayer HealthCare has sued Mylan Pharmaceuticals over the alleged infringement of five of its patents.
Asia
16 July 2014   The Mumbai High Court has upheld India-based Natco Pharma’s compulsory licence on Bayer’s kidney cancer drug Nexavar (sorafenib).